Cargando…
Real world data in health technology assessments in kidney transplants in Germany: use of routinely collected data to address epidemiologic questions in kidney transplants in the AMNOG process in Germany
Introduction: It is discussed whether real world data can be used in health technology assessment. Following it is of interest whether routinely collected data for quality assurance (QA) in the hospital sector is feasible to address epidemiologic questions in kidney transplantation in the AMNOG proc...
Autores principales: | Herrmann, Kirsten H., Meier-Kriesche, Ulf, Neubauer, Aljoscha S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
German Medical Science GMS Publishing House
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5800357/ https://www.ncbi.nlm.nih.gov/pubmed/29472834 http://dx.doi.org/10.3205/000263 |
Ejemplares similares
-
10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?
por: Büssgen, Melanie, et al.
Publicado: (2023) -
Impact of the introduction of the AMNOG law on launch delays of new drugs in Germany: a comment
por: Gandjour, Afschin
Publicado: (2023) -
How Far is Germany From Value-Based Pricing 10 Years After the Introduction of AMNOG?
por: Dintsios, Charalabos-Markos, et al.
Publicado: (2021) -
“Market withdrawals” of medicines in Germany after AMNOG: a comparison of HTA ratings and clinical guideline recommendations
por: Staab, Thomas R., et al.
Publicado: (2018) -
Early benefit assessment (EBA) in Germany: analysing decisions 18 months after introducing the new AMNOG legislation
por: Ruof, Jörg, et al.
Publicado: (2013)